---
title: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
date: '2023-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37962077/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231114170829&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Treatment with elafibranor resulted in significantly greater
  improvements in relevant biochemical indicators of cholestasis than placebo. (Funded
  by GENFIT and Ipsen; ELATIVE ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Treatment with elafibranor resulted in significantly greater improvements in relevant biochemical indicators of cholestasis than placebo. (Funded by GENFIT and Ipsen; ELATIVE ClinicalTrials.gov number, ...